Bowden Christopher - Stock Option Grant

Christopher Bowden, a director at Bicara Therapeutics Inc. (BCAX), was granted a stock option on June 9, 2026, for 19,475 shares of Common Stock at an exercise price of $20.56. The option vests upon the earlier of June 9, 2027, or the next Annual Meeting of Stockholders, contingent upon continued service. The option has an expiration date of June 9, 2036. This filing is a Form 4, indicating a change in beneficial ownership.